Long Non-Coding RNAs in Non-Alcoholic Fatty Liver Disease; Friends or Foes?

• Published in: Cell biochemistry and biophysics 2024-10
• Main Authors: Soltanieh, Sina Kalantari, Khastar, Sahar, Kaur, Irwanjot, Kumar, Abhishek, Bansal, Jaya, Fateh, Ata, Nathiya, Deepak, Husseen, Beneen, Rajabivahid, Mansour, Dehghani-Ghorbi, Mahmoud, Akhavan-Sigari, Reza
• Format: Article
• Language: English
• ISSN: 1085-9195; 1559-0283; 1559-0283
• DOI: 10.1007/s12013-024-01555-8

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a range of conditions that start with the accumulation of fat in the liver (hepatic steatosis) and can progress to more severe stages like steatohepatitis (NASH) and fibrosis without drinking alcohol. Environmental and genetic variables both contribute to MAFLD's development, with various biological processes and mediators involved at every phase. Long non-coding RNAs (lncRNAs) are a class of RNA molecules that are not translated into protein and are over 200 nucleotides long. They can impact genes that encode protein by controlling transcriptional and post-transcriptional procedures. Dysregulation of lncRNA has been connected to several liver diseases, including MAFLD. Recent research has linked lncRNAs to MAFLD pathology in both patients and animal models. However, the roles of most lncRNAs in MAFLD pathology are still not well recognized. This review provides a comprehensive catalog of recently reported lncRNAs in the pathogenesis of MAFLD and summarizes the current knowledge of lncRNAs usage as therapeutic strategies in MAFLD, the most common liver disease. Collectively, lncRNA's targeting could potentially offer a therapeutic approach by modulating MAFLD.